278 related articles for article (PubMed ID: 17576024)
41. Functional antibodies elicited by two heptavalent pneumococcal conjugate vaccines in the Finnish Otitis Media Vaccine Trial.
Ekström N; Väkeväinen M; Verho J; Kilpi T; Käyhty H
Infect Immun; 2007 Apr; 75(4):1794-800. PubMed ID: 17261612
[TBL] [Abstract][Full Text] [Related]
42. Does the 23-valent pneumococcal vaccine protect cochlear implant recipients?
Hey C; Rose MA; Kujumdshiev S; Gstoettner W; Schubert R; Zielen S
Laryngoscope; 2005 Sep; 115(9):1586-90. PubMed ID: 16148699
[TBL] [Abstract][Full Text] [Related]
43. A randomized, double-blind trial of pneumococcal vaccination in adult allogeneic stem cell transplant donors and recipients.
Kumar D; Chen MH; Welsh B; Siegal D; Cobos I; Messner HA; Lipton J; Humar A
Clin Infect Dis; 2007 Dec; 45(12):1576-82. PubMed ID: 18190318
[TBL] [Abstract][Full Text] [Related]
44. Immunogenicity, safety and tolerability of heptavalent pneumococcal conjugate vaccine administered at 3, 5 and 11 months post-natally to pre- and full-term infants.
Esposito S; Pugni L; Bosis S; Proto A; Cesati L; Bianchi C; Cimino C; Mosca F; Principi N
Vaccine; 2005 Feb; 23(14):1703-8. PubMed ID: 15705475
[TBL] [Abstract][Full Text] [Related]
45. Validation of current joint American Academy of Allergy, Asthma & Immunology and American College of Allergy, Asthma and Immunology guidelines for antibody response to the 23-valent pneumococcal vaccine using a population of HIV-infected children.
Kamchaisatian W; Wanwatsuntikul W; Sleasman JW; Tangsinmankong N
J Allergy Clin Immunol; 2006 Dec; 118(6):1336-41. PubMed ID: 17157665
[TBL] [Abstract][Full Text] [Related]
46. Pneumococcal conjugate vaccination does not induce a persisting mucosal IgA response in children with recurrent acute otitis media.
Bogaert D; Veenhoven RH; Ramdin R; Luijendijk IH; Rijkers GT; Sanders EA; de Groot R; Hermans PW
Vaccine; 2005 Apr; 23(20):2607-13. PubMed ID: 15780443
[TBL] [Abstract][Full Text] [Related]
47. Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for use of 7-valent pneumococcal conjugate vaccine (PCV7) in children aged 24-59 months who are not completely vaccinated.
;
MMWR Morb Mortal Wkly Rep; 2008 Apr; 57(13):343-4. PubMed ID: 18385642
[TBL] [Abstract][Full Text] [Related]
48. Immunogenicity of sequential pneumococcal vaccination in subjects splenectomised for hereditary spherocytosis.
Stoehr GA; Rose MA; Eber SW; Heidemann K; Schubert R; Zielen S
Br J Haematol; 2006 Mar; 132(6):788-90. PubMed ID: 16487181
[TBL] [Abstract][Full Text] [Related]
49. Poor antibody response to pneumococcal polysaccharide vaccination suggests increased susceptibility to pneumococcal infection in splenectomized patients with hematological diseases.
Cherif H; Landgren O; Konradsen HB; Kalin M; Björkholm M
Vaccine; 2006 Jan; 24(1):75-81. PubMed ID: 16107293
[TBL] [Abstract][Full Text] [Related]
50. Immune memory in children previously vaccinated with an experimental quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine.
Pichichero M; Papa T; Blatter M; Mitchell D; Kratz R; Sneed J; Bassily E; Casey J; Gilmet G
Pediatr Infect Dis J; 2006 Nov; 25(11):995-1000. PubMed ID: 17072120
[TBL] [Abstract][Full Text] [Related]
51. Heptavalent pneumococcal conjugate vaccine: current and future impact.
Hsu KK; Pelton SI
Expert Rev Vaccines; 2003 Oct; 2(5):619-31. PubMed ID: 14711324
[TBL] [Abstract][Full Text] [Related]
52. Safety of varying dosages of 7-valent pneumococcal protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Jackson LA; Neuzil KM; Whitney CG; Starkovich P; Dunstan M; Yu O; Nelson JC; Feikin DR; Shay DK; Baggs J; Carste B; Nahm MH; Carlone G
Vaccine; 2005 May; 23(28):3697-703. PubMed ID: 15882530
[TBL] [Abstract][Full Text] [Related]
53. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection.
Nachman S; Kim S; King J; Abrams EJ; Margolis D; Petru A; Shearer W; Smith E; Moye J; Blanchard S; Hawkins E; Bouquin P; Vink P; Benson M; Estep S; Malinoski F;
Pediatrics; 2003 Jul; 112(1 Pt 1):66-73. PubMed ID: 12837869
[TBL] [Abstract][Full Text] [Related]
54. [Study on the safety and immunogenicity of group A + C meningococcal polysaccharide vaccine].
He L; Li RC; Li YN; Huang YN; Yao Q; Yuan ZL; Li FX; Cui XL; Nong Y; Yang M
Zhonghua Liu Xing Bing Xue Za Zhi; 2007 May; 28(5):422-5. PubMed ID: 17877165
[TBL] [Abstract][Full Text] [Related]
55. Invasive pneumococcal disease in Portugal prior to and after the introduction of pneumococcal heptavalent conjugate vaccine.
Dias R; Caniça M
FEMS Immunol Med Microbiol; 2007 Oct; 51(1):35-42. PubMed ID: 17854472
[TBL] [Abstract][Full Text] [Related]
56. American Academy of Pediatrics. Committee on Infectious Diseases. Policy statement: recommendations for the prevention of pneumococcal infections, including the use of pneumococcal conjugate vaccine (Prevnar), pneumococcal polysaccharide vaccine, and antibiotic prophylaxis.
Pediatrics; 2000 Aug; 106(2 Pt 1):362-6. PubMed ID: 10920169
[TBL] [Abstract][Full Text] [Related]
57. Administration of protein-conjugate pneumococcal vaccine to patients who have invasive disease after splenectomy despite their having received 23-valent pneumococcal polysaccharide vaccine.
Musher DM; Ceasar H; Kojic EM; Musher BL; Gathe JC; Romero-Steiner S; White AC
J Infect Dis; 2005 Apr; 191(7):1063-7. PubMed ID: 15747240
[TBL] [Abstract][Full Text] [Related]
58. [Two pneumococcal vaccines: the 7-valent conjugate vaccine (Prevenar) for children up to the age of 5 years and the 23-valent polysaccharide vaccine (Pneumo 23) for the elderly and specific groups at risk].
de Greeff SC; Sanders EA; de Melker HE; van der Ende A; Vermeer PE; Schouls LM
Ned Tijdschr Geneeskd; 2007 Jun; 151(26):1454-7. PubMed ID: 17633974
[TBL] [Abstract][Full Text] [Related]
59. Infant immunisation with a pneumococcal conjugate vaccine: from the age of two months, for all infants.
Prescrire Int; 2006 Dec; 15(86):227-33. PubMed ID: 17167934
[TBL] [Abstract][Full Text] [Related]
60. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life.
Adamkiewicz TV; Silk BJ; Howgate J; Baughman W; Strayhorn G; Sullivan K; Farley MM
Pediatrics; 2008 Mar; 121(3):562-9. PubMed ID: 18310206
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
